Pfizer Scores FDA Approval on New Class of RA Drug … XELJANZ
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration approved its drug candidate called XELJANZ. The treatment here is for rheumatoid arthritis and this is the ...Read Full Story »
